David A. Lipson

David A. Lipson's AcademicInfluence.com Rankings

David A. Lipson

Physics

#7617

World Rank

#9662

Historical Rank

physics Degrees

Download Badge

Physics

David A. Lipson's Degrees

PhD Physics Stanford University
Masters Physics Stanford University
Bachelors Physics Stanford University

Why Is David A. Lipson Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David A. Lipson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A communal catalogue reveals Earth’s multiscale microbial diversity (2017) (1501)
Manual of environmental microbiology. (2007) (1025)
Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD (2018) (759)
Seasonal Dynamics of Previously Unknown Fungal Lineages in Tundra Soils (2003) (593)
A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome (2017) (494)
The unexpected versatility of plants: organic nitrogen use and availability in terrestrial ecosystems (2001) (431)
Viral and microbial community dynamics in four aquatic environments (2010) (378)
LINKS BETWEEN MICROBIAL POPULATION DYNAMICS AND NITROGEN AVAILABILITY IN AN ALPINE ECOSYSTEM (1999) (376)
Seasonal Changes in an Alpine Soil Bacterial Community in the Colorado Rocky Mountains (2004) (355)
Cold season emissions dominate the Arctic tundra methane budget (2015) (295)
Changes in Soil Microbial Community Structure and Function in an Alpine Dry Meadow Following Spring Snow Melt (2002) (290)
FULFIL Trial: Once‐Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (2017) (269)
Carbon availability and temperature control the post-snowmelt decline in alpine soil microbial biomass (2000) (238)
Plant-microbe competition for soil amino acids in the alpine tundra: effects of freeze-thaw and dry-rewet events (1998) (227)
Microbial growth under the snow: Implications for nutrient and allelochemical availability in temperate soils (2004) (220)
SOIL AMINO ACID UTILIZATION AMONG SPECIES OF THE CYPERACEAE: PLANT AND SOIL PROCESSES (1999) (207)
Methane fluxes during the initiation of a large‐scale water table manipulation experiment in the Alaskan Arctic tundra (2009) (175)
Risk factors for death of patients with cystic fibrosis awaiting lung transplantation. (2006) (174)
Cultivation of bacteria and fungi. (2007) (169)
A Combined Pulmonary-Radiology Workshop for Visual Evaluation of COPD: Study Design, Chest CT Findings and Concordance with Quantitative Evaluation (2012) (161)
The complex relationship between microbial growth rate and yield and its implications for ecosystem processes (2015) (150)
Reduction of iron (III) and humic substances plays a major role in anaerobic respiration in an Arctic peat soil (2010) (135)
Relationships between temperature responses and bacterial community structure along seasonal and altitudinal gradients. (2007) (135)
Variation in competitive abilities of plants and microbes for specific amino acids (1999) (134)
Non-mycorrhizal uptake of amino acids by roots of the alpine sedge Kobresia myosuroides: implications for the alpine nitrogen cycle (1996) (133)
Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. (2019) (131)
Effects of Elevated Atmospheric CO2 on Soil Microbial Biomass, Activity, and Diversity in a Chaparral Ecosystem (2005) (128)
A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol (2016) (122)
The trade-off between growth rate and yield in microbial communities and the consequences for under-snow soil respiration in a high elevation coniferous forest (2009) (117)
The contribution of beneath‐snow soil respiration to total ecosystem respiration in a high‐elevation, subalpine forest (2006) (111)
An Oral Inhibitor of p38 MAP Kinase Reduces Plasma Fibrinogen in Patients With Chronic Obstructive Pulmonary Disease (2012) (111)
Metagenomic Insights into Anaerobic Metabolism along an Arctic Peat Soil Profile (2013) (107)
Metabolic trade-offs and the maintenance of the fittest and the flattest (2011) (106)
Microtopographic controls on ecosystem functioning in the Arctic Coastal Plain (2011) (101)
Bronchoscopy for atelectasis in the ICU: a case report and review of the literature. (2003) (101)
Grass invasion causes rapid increases in ecosystem carbon and nitrogen storage in a semiarid shrubland (2010) (98)
Molecular and Metabolic Characterization of Cold-Tolerant Alpine Soil Pseudomonas Sensu Stricto (2004) (96)
Water-table height and microtopography control biogeochemical cycling in an Arctic coastal tundra ecosystem (2011) (88)
Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study (2017) (86)
Determination of regional VA/Q by hyperpolarized 3He MRI (2004) (85)
Biotransformations of Manganese (2007) (85)
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease (2020) (82)
Direct visualisation of collateral ventilation in COPD with hyperpolarised gas MRI (2011) (81)
An empirical model of amino acid transformations in an alpine soil (2001) (77)
GI complications after orthotopic lung transplantation. (1996) (70)
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial (2019) (67)
Effects of Abiotic Factors on the Phylogenetic Diversity of Bacterial Communities in Acidic Thermal Springs (2007) (67)
Waterborne Transmission of Infectious Agents (2007) (66)
Relationships Between Microbial Community Structure and Soil Processes Under Elevated Atmospheric Carbon Dioxide (2006) (62)
Luxury Uptake and Storage of Nitrogen in the Rhizomatous Alpine Herb, Bistorta Bistortoides (1996) (61)
The contribution of Fe(III) and humic acid reduction to ecosystem respiration in drained thaw lake basins of the Arctic Coastal Plain (2013) (60)
Impacts of chronic nitrogen additions vary seasonally and by microbial functional group in tundra soils (2004) (58)
Methane suppression by iron and humic acids in soils of the Arctic Coastal Plain (2015) (57)
Pulmonary ventilation and perfusion scanning using hyperpolarized helium‐3 MRI and arterial spin tagging in healthy normal subjects and in pulmonary embolism and orthotopic lung transplant patients (2002) (57)
Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF-α Receptor 1 (2013) (57)
Soil microbial responses to drought and exotic plants shift carbon metabolism (2019) (55)
Growth of Eastern Cottonwoods (Populus deltoides) in elevated [CO2] stimulates stand‐level respiration and rhizodeposition of carbohydrates, accelerates soil nutrient depletion, yet stimulates above‐ and belowground biomass production (2005) (54)
Exponential growth of “snow molds” at sub-zero temperatures: an explanation for high beneath-snow respiration rates and Q10 values (2009) (52)
Global biogeography of fungal and bacterial biomass carbon in topsoil (2020) (49)
A cost-effective and field-ready potentiostat that poises subsurface electrodes to monitor bacterial respiration. (2012) (49)
Changes in microbial communities along redox gradients in polygonized Arctic wet tundra soils. (2015) (48)
Increased CO2 loss from vegetated drained lake tundra ecosystems due to flooding (2012) (48)
Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study (2018) (47)
Nitrogen and carbon storage in alpine plants. (2006) (44)
Manual of Environmental Microbiology, Third Edition (2007) (44)
Microbial diversity in nonsulfur, sulfur and iron geothermal steam vents. (2011) (44)
Microbial macroecology: In search of mechanisms governing microbial biogeographic patterns (2020) (43)
Ectomycorrhizal transfer of amino acid‐nitrogen to the alpine sedge Kobresia myosuroides (1999) (43)
Effects of Willows (Salix brachycarpa) on Populations of Salicylate-Mineralizing Microorganisms in Alpine Soils (2000) (42)
Top-down control of microbial activity and biomass in an Arctic soil ecosystem. (2010) (41)
Analytical imaging and microscopy techniques. (2007) (40)
Microbial biomass levels in barren and vegetated high altitude talus soils (2001) (40)
Perfusion scintigraphy and patient selection for lung volume reduction surgery. (2010) (39)
Measurements of regional alveolar oxygen pressure using hyperpolarized 3He MRI. (2005) (37)
Hyperpolarized 13C MRI of the pulmonary vasculature and parenchyma (2007) (36)
Demonstration of a compact compressor for application of metastability‐exchange optical pumping of 3He to human lung imaging (2000) (35)
Inappropriate antibiotic prescribing in managed care subjects with influenza. (2011) (34)
Giant Gastric Ulcers and Risk Factors for Gastroduodenal Mucosal Disease in Orthotopic Lung Transplant Patients (1998) (34)
The evaluation and preparation of the patient for lung volume reduction surgery. (2008) (33)
The adenosine 2A receptor agonist GW328267C improves lung function after acute lung injury in rats. (2012) (31)
Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient. (2005) (30)
Detection and localization of pulmonary air leaks using laser‐polarized 3He MRI (2000) (30)
Elevated atmospheric CO2 stimulates soil fungal diversity through increased fine root production in a semiarid shrubland ecosystem (2014) (30)
Detection of simulated pulmonary embolism in a porcine model using hyperpolarized 3He MRI (2004) (29)
Differential responses of native and exotic coastal sage scrub plant species to N additions and the soil microbial community (2013) (29)
Overview of the perioperative management of lung volume reduction surgery patients. (2008) (28)
Microbial community structure and soil pH correspond to methane production in Arctic Alaska soils (2017) (28)
Delayed responses of an Arctic ecosystem to an extreme summer: impacts on net ecosystem exchange and vegetation functioning (2013) (28)
Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life (2018) (28)
A Randomized Dose-Escalation Study of the Safety and Anti-Inflammatory Activity of the p38 Mitogen-Activated Protein Kinase Inhibitor Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome (2015) (28)
A small animal model of regional alveolar ventilation using HP 3He MRI1. (2004) (26)
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients. (2020) (26)
Airborne bacteria and endotoxin. (2007) (25)
3He pO2 mapping is limited by delayed‐ventilation and diffusion in chronic obstructive pulmonary disease (2014) (25)
Quantitative assessment of emphysema using hyperpolarized 3He magnetic resonance imaging (2005) (25)
Apical perfusion fraction as a predictor of short-term functional outcome following bilateral lung volume reduction surgery. (2001) (24)
Dynamic observation of pulmonary perfusion using continuous arterial spin‐labeling in a pig model (2001) (22)
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials (2020) (21)
Co‐registration of acquired MR ventilation and perfusion images—Validation in a porcine model (2003) (21)
Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial (2017) (21)
Mechanistic Modeling of Microtopographic Impacts on CO2 and CH4 Fluxes in an Alaskan Tundra Ecosystem Using the CLM‐Microbe Model (2019) (20)
Preventing clinically important deterioration with single-inhaler triple therapy in COPD (2018) (20)
Snow melt stimulates ecosystem respiration in Arctic ecosystems (2020) (19)
Anaerobic Methane Oxidation in High-Arctic Alaskan Peatlands as a Significant Control on Net CH4 Fluxes (2019) (19)
The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial (2020) (18)
Hyperpolarized helium-3 MR imaging of pulmonary function. (2005) (17)
Imaging physiological parameters with hyperpolarized gas MRI (2005) (16)
The effect of exacerbation history on outcomes in the IMPACT trial (2020) (16)
Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses (2018) (16)
Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis (2018) (16)
Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. (1998) (15)
Operating characteristics of hyperpolarized 3He and arterial spin tagging in MR imaging of ventilation and perfusion in healthy subjects. (2003) (15)
Functional lung imaging (2005) (15)
The IMPACT Study – Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population (2019) (14)
Measuring disease activity in COPD: is clinically important deterioration the answer? (2020) (14)
The fate of biological soil crusts after fire: A meta-analysis (2020) (14)
Single-Inhaler Triple versus Dual Therapy in Patients with COPD. (2018) (13)
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis (2018) (12)
Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials. (2019) (12)
Potentiostatically Poised Electrodes Mimic Iron Oxide and Interact with Soil Microbial Communities to Alter the Biogeochemistry of Arctic Peat Soils (2013) (12)
Phosphorus alleviation of nitrogen-suppressed methane sink in global grasslands. (2020) (12)
Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis (2019) (11)
Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT (2018) (11)
The Influence of Altered Rainfall Regimes on Early Season N Partitioning Among Early Phenology Annual Plants, a Late Phenology Shrub, and Microbes in a Semi-arid Ecosystem (2014) (10)
The Rhizosphere: A Synchrotron-Based View of Nutrient Flow in the Root Zone (2010) (10)
Effects of umeclidinium/vilanterol on exercise endurance in COPD: a randomised study (2018) (10)
Controls on soil microbial carbon use efficiency over long-term ecosystem development (2021) (9)
Seasonal Patterns of Dry Deposition at a High‐Elevation Site in the Colorado Rocky Mountains (2017) (9)
The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial) (2018) (9)
Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD (2021) (9)
Temperature Response of Respiration Across the Heterogeneous Landscape of the Alaskan Arctic Tundra (2018) (8)
Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials (2018) (8)
Drought in Southern California coastal sage scrub reduces herbaceous biomass of exotic species more than native species, but exotic growth recovers quickly when drought ends (2019) (7)
Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial (2020) (7)
Comparative Efficacy and Safety of Umeclidinium/Vilanterol, Umeclidinium and Salmeterol in Symptomatic Maintenance-Naïve and Maintenance-Treated Chronic Obstructive Pulmonary Disease: A Pre-Specified Secondary Analysis of the EMAX Trial (2019) (7)
Blood eosinophil counts and treatment response in COPD: analyses of IMPACT (2018) (6)
International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials (2022) (6)
Detection and localization of pulmonary air leaks using laser-polarized (3)He MRI. (2000) (6)
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial (2020) (6)
Isolation, enumeration, growth, and preservation of acidophilic prokaryotes. (2007) (6)
InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations (2021) (6)
Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial (2021) (6)
Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease (2019) (6)
Dynamics of Fungal and Bacterial Biomass Carbon in Natural Ecosystems: Site‐Level Applications of the CLM‐Microbe Model (2020) (6)
Plant community composition alters moisture and temperature sensitivity of soil respiration in semi-arid shrubland (2021) (5)
Locating and Selecting Appraisal Studies for Reviews (2004) (5)
Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial. (2021) (5)
Tension pneumoperitoneum associated with a pleural-peritoneal shunt. (1999) (5)
Reply to Suissa: Mortality in IMPACT: Confounded by Asthma? (2020) (5)
Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial (2020) (5)
The adenosine 2 A receptor agonist GW 328267 C improves lung function after acute lung injury in rats (2012) (5)
Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement (2021) (5)
δ-Acetylornithine as a major nitrogen storage compound in Bistorta bistortoides (1996) (5)
Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study (2020) (5)
Multiple regression method for pulmonary apparent diffusion coefficient measurement by hyperpolarized 3He MRI (2007) (5)
Biological chlorine cycling in the Arctic Coastal Plain (2017) (5)
Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD (2018) (5)
xZlamalRaab_Clorg (2017).pdf (2017) (4)
Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD (4)
Exotic herbaceous species interact with severe drought to alter soil N cycling in a semi-arid shrubland (2020) (4)
Analysis of IMPACT: is one blood eosinophil count measurement sufficient to predict ICS treatment response in COPD? (2019) (4)
Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial (2020) (4)
Discordant diagnostic criteria for pneumonia in COPD trials: a review (2021) (4)
Alternatives to lung transplantation: lung volume reduction surgery and continuous intravenous prostacyclin. (2002) (4)
Groundwater-surface water interactions and flux of organic matter and nutrients in an urban, Mediterranean stream. (2021) (4)
Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis (2021) (4)
Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice (2021) (4)
Reduction in the Risk of All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol Compared to Umeclidinium/Vilanterol in IMPACT Including Previously Missing or Censored Vital Status Data (2019) (4)
One More Time: The Impact of Inhaled Corticosteroid Withdrawal on IMPACT (2020) (3)
Kinetics of Microbial Processes and Population Growth in Soil (2003) (3)
Noninvasive ventilation [1] (multiple letters) (2004) (3)
Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of the IMPACT Trial. (2020) (3)
Redefining Treatment in COPD (2004) (3)
Single inhaler triple therapy in advanced COPD patients: prior medication and disease severity FULFIL subanalyses (2017) (3)
Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial (2021) (3)
Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study (2017) (3)
Time‐Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial (2022) (3)
A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial (2021) (3)
Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial (2018) (3)
Reply to: ‘evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies’ (2020) (3)
Dust deposition drives microbial metabolism in a remote, high-elevation catchment (2020) (3)
Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial (2021) (2)
Aboveground competition influences density‐dependent effects of cordgrass on sediment biogeochemistry (2022) (2)
Gastrointestinal Complications of Acute Respiratory Failure (2003) (2)
Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD (2021) (2)
Genetics plays a limited role in predicting chronic obstructive pulmonary disease treatment response and exacerbation. (2021) (2)
InforMing the PAthway of COPD Treatment Single-Inhaler Triple Therapy (Fluticasone Furoate/ Umeclidinium/ Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium /Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions. (2020) (2)
The IMPACT Trial: Single Inhaler Triple Therapy fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Analysis According to Smoking Status (2019) (2)
P272 Improvements in exacerbation rates with single inhaler triple therapy versus dual ics/laba therapy in patients with advanced chronic obstructive pulmonary disease (copd): subgroup analyses of the phase iii fulfil study (2017) (2)
The Unmet Need of Moderate Exacerbations Among Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiated Inhaled Maintenance Therapy in United Kingdom (UK) General Practice (2019) (2)
Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial (2019) (2)
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial (2022) (2)
Years After a Fire, Biocrust Microbial Communities are Similar to Unburned Communities in a Coastal Grassland (2022) (2)
Reply to Suissa and Ariel: The FULFIL Trial. (2017) (2)
Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD: a post hoc analysis of the EMAX randomised controlled trial (2020) (2)
Differentiation of Vasculopathy from Normal Pulmonary Vasculature Using Hyperpolarized Helium-3 MRI in Humans (2006) (2)
MRI of delayed-ventilation perfusion matching in COPD (2012) (2)
Comparison of LAMA/LABA vs. ICS/LABA in high risk COPD patients: Pre-specified analysis on lung function and health status from the IMPACT trial (2018) (2)
Facilitating Restoration of Degraded Biological Soil Crusts Using Mixed Culture Inoculation (2023) (2)
Bronchodilator treatment response mapping in COPD using hyperpolarised gas ventilation MRI (2013) (2)
LATE-BREAKING ABSTRACT: Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: Results of the FULFIL trial (2016) (2)
Noble Gas Ventilation Imaging Using 3He and 129 Xe: An Introduction (2005) (1)
FF/UMEC/VI versus FF/VI and UMEC/VI in the ELLIPTA device in patients with COPD: Subgroup analyses from the IMPACT trial (2018) (1)
Risk of All-Cause Mortality During and After Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease (COPD): Post Hoc Analysis of the IMPACT Trial (2021) (1)
TREATMENT EFFECTS OF FF/UMEC/VI VS FF/VI AND UMEC/VI IN REVERSIBLE AND NONREVERSIBLE COPD PATIENTS: ANALYSES OF THE IMPACT STUDY (2018) (1)
Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT (2020) (1)
Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England (2022) (1)
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model (2021) (1)
Invasion of a semi-arid shrubland by annual grasses increases autotrophic and heterotrophic soil respiration rates due to altered soil moisture and temperature patterns (2010) (1)
24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study (2020) (1)
The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time (2019) (1)
Reply: "FULFIL an Unmet Need in Chronic Obstructive Pulmonary Disease" and "Triple Therapy in Chronic Obstructive Pulmonary Disease". (2017) (1)
Reply to Morice and Hart: Increased Propensity for Pneumonia with Fluticasone in Chronic Obstructive Pulmonary Disease. (2017) (1)
Automated total and heterotrophic soil respiration in semi-arid shrubland and annual invasive patches (2021) (1)
Letter to editor – a response to: ‘efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review’ (2021) (1)
Misinterpretation of time-to-first event curves can lead to inappropriate treatment (2019) (1)
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis. (2022) (1)
EFFECT OF ONCE-DAILY SINGLE-INHALER FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL TRIPLE THERAPY ON SEVERE EXACERBATION RATES COMPARED WITH TWICE-DAILY BUDESONIDE/FORMOTEROL DUAL THERAPY IN PATIENTS WITH COPD: A POST HOC ANALYSIS OF THE FULFIL STUDY (2021) (1)
An Analysis of the IMPACT Trial Assessing Single-Inhaler Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI and UMEC/VI Using a Composite Adverse Event Outcome in Patients with COPD (2021) (1)
Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial (2022) (1)
Imaging of bronchodilator effects in COPD with hyperpolarised 3He and 1H MRI (2013) (1)
Biological Chlorine Cycling in Arctic Peat Soils (2014) (1)
Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy: two replicate trials in patients with chronic obstructive pulmonary disease (COPD) (2020) (1)
Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: German responder results for patient reported symptom E-RS and subscale analyses from the FULFIL trial (2018) (1)
Late Breaking Abstract - Influence of salbutamol use on symptomatic outcomes with maintenance bronchodilators: a pre-specified analysis of the EMAX trial (2019) (1)
Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study (2020) (1)
Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared with Tiotropium Monotherapy in Patients with Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations (2020) (1)
Population pharmacokinetic (PK) analysis of fluticasone furoate (FF)/umeclidimium (UMEC)/vilanterol (VI) via a single inhaler in patients with COPD (FULFIL) (2017) (1)
Reduction in Emergency Department (ED) Visits in Patients with Chronic Obstructive Pulmonary Disease (COPD): Analysis of the IMPACT Trial (2021) (1)
Perfusion Scintigraphy as a Prognostic Tool for Lung Volume Reduction Surgery Outcomes. (2009) (1)
Teaching Case: Improvement of Chronic Chylous Pleural Effusion Using a Restricted Fat Diet and Medium Chain Triglycerides in a Patient with Congenital Lymphangiectasia (2000) (1)
Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients with COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial (2020) (1)
Ecosystem Scale Implication of Soil CO2 Concentration Dynamics During Soil Freezing in Alaskan Arctic Tundra Ecosystems (2021) (1)
Quantifying lung function in COPD with hyperpolarised 3He MRI (2012) (1)
RISK OF DEATH AND COPD HOSPITALIZATION WITH FLUTICASONE FUROATE-CONTAINING THERAPY: POST HOC SUBGROUP ANALYSIS FROM THE SUMMIT TRIAL IN PATIENTS WITH COPD AND A HISTORY OF EXACERBATION (2020) (1)
Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial (2020) (0)
Symptom improvement over time with umeclidinium/vilanterol versus monotherapy: a post-hoc analysis of the EMAX trial (2019) (0)
Functional imaging of the lung parenchyma , tumours and circulation (2012) (0)
Umeclidinium/vilanterol in preventing clinically important deterioration (CID) in COPD and impact of baseline disease severity: the EMAX trial (2019) (0)
Toward optimal health: the experts discuss chronic obstructive pulmonary disease in women. Interview by Jody Godfrey. (2004) (0)
P275 Comparing clinically relevant improvement with umeclidinium/vilanterol and tiotropium/olodaterol in symptomatic copd: a randomised non-inferiority crossover trial (2017) (0)
Cystic Fibrosis: Radiologic Considerations (2005) (0)
Surgical Options in Chronic Obstructive Pulmonary Disease (2006) (0)
Soil microbial responses to drought and exotic plants shift carbon metabolism (2019) (0)
Exploring the Comparative Efficacy and Safety of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol in Moderate Symptomatic COPD: A Randomized Non-Inferiority Crossover Trial (2017) (0)
COMPARISON BETWEEN FF/UMEC/VI VS UMEC/VI AND FF/VI AND UMEC/VI VS FF/VI BASED ON BASELINE EXACERBATION HISTORY AND FEV1: SUB-ANALYSIS FROM THE IMPACT TRIAL (2019) (0)
Exacerbation and pneumonia risk models: methodology and results from the IMPACT trial (2019) (0)
Utilization of subsurface microbial electrochemical systems to elucidate the mechanisms of competition between methanogenesis and microbial iron(III)/humic acid reduction in Arctic peat soils (2012) (0)
Interactive comment on “ Water table height and microtopography control biogeochemical cycling in an Arctic coastal tundra ecosystem ” by D . A (2011) (0)
Organohalide-Respiring Bacteria at the Heart of Anaerobic Metabolism in Arctic Wet Tundra Soils (2020) (0)
Arctic Methane Flux from Wet-Sedge Tundra: Impact of Fe(III) additions, Spatial Heterogeneity and Season (2011) (0)
The distribution of blood eosinophil count in the IMPACT South America population (2020) (0)
62: Effect of donor glutathione-S-transferase genotype on the development of bronchiolitis obliterans syndrome after lung transplantation (2006) (0)
COPD_A_226601 2849..2861 (2019) (0)
Combined MR Ventilation/Perfusion Imaging (2005) (0)
Methods for soil metagenomics: extraction and cloning of soil DNA. (2007) (0)
Phosphorus Alleviation of Nitrogen-Suppressed Methane Sink in Global Grasslands (2020) (0)
Single inhaler triple therapy in patients with advanced COPD: healthcare resource utilisation and cost data from the FULFIL study (2017) (0)
TREATMENT EFFECTS OF FF/UMEC/VI VS FF/VI AND UMEC/VI IN COPD PATIENTS BY AIRFLOW LIMITATION SEVERITY: POST-HOC ANALYSES OF THE IMPACT STUDY (2018) (0)
Wetting increases respiration loss from the Arctic tundra (2010) (0)
Functional magnetic resonance imaging of the lung (2003) (0)
Single inhaler triple therapy in patients with advanced COPD (FULFIL): exacerbation/pneumonia composite outcomes (2017) (0)
Reply to: The Role of Eosinophil During the Withdrawal of Inhaled Corticosteroid in COPD. (2020) (0)
Title A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome (2017) (0)
Introduction and overview: soil, rhizosphere, and phyllosphere. (2007) (0)
PRS10 Economic Evaluation of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol in a UK COPD Population at Low Risk of Exacerbations Using the GALAXY Model (2021) (0)
Suppl Methods for Biogeochemistry paper (2017) (0)
The Relationship between Radiographic Emphysema and Lung Perfusion. (2009) (0)
The Effect of a Reduction in Microbial Diversity on Greenhouse Gas Production in Alaskan Tundra Soils. (2017) (0)
Reply to Lipworth and Jabbal, and to Singh and Vestbo. (2017) (0)
Noninvasive ventilation. (2004) (0)
BENEFIT–RISK PROFILES OF FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) VS UMEC/VI IN PATIENTS WITH COPD: A MARKOV MODEL (2020) (0)
Improving COPD symptoms with umeclidinium/vilanterol and impact of baseline disease severity: the EMAX trial (2019) (0)
Methane Suppression: The Impacts of Fe(III) and Humic Acids on Net Methane Flux from Arctic Tundra Wetlands in Alaska and Finland (Invited) (2013) (0)
Microbial Community Structure and Soil pH Predict Methane Production in Alaskan Tussock Tundra (2016) (0)
Improving daily COPD symptoms, as measured using the E-RS, with umeclidinium/vilanterol versus monotherapy: the EMAX trial (2019) (0)
Drought in Southern California coastal sage scrub reduces herbaceous biomass of exotic species more than native species, but exotic growth recovers quickly when drought ends (2019) (0)
Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD. (2022) (0)
Plant-Microbe Interactions (2013) (0)
Comparison of individual items of COPD Assessment Test (CAT) at baseline in the EMAX and IMPACT trials (2020) (0)
Soluble Iron as an In Situ Indicator of the Redox State of Humic Substances in Arctic Soil: Implications for Seasonal Regeneration of Oxidized Terminal Electron Acceptors (2014) (0)
TIME-DEPENDENT RISK OF CARDIOVASCULAR EVENTS FOLLOWING AN EXACERBATION IN PATIENTS WITH COPD: POST HOC ANALYSIS FROM THE IMPACT TRIALl (2020) (0)
S118 Direct visualisation of collateral ventilation in COPD with hyperpolarised Gas MRI (2011) (0)
Best Practice Management of Patients With Chronic Obstructive Pulmonary Disease: A Case-Based Review (2022) (0)
Reply to López-Campos et al.: Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect (2021) (0)
Eighty-five percent of terrestrial methane emissions arise from a single landscape feature type during spring thaw in Barrow, Alaska. (2018) (0)
Correction to: Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study (2022) (0)
A simple clinical predictive model for primary graft failure following lung transplantation (2003) (0)
Biogeosciences 2012 bg-9-577-2012 (2012) (0)
PNEUMOTHORAX DETECTED BY NOVEL MRI VENTILATION/PERFUSION SCANNING USING NON-RADIOACTIVE HYPERPOLARIZED 3HE AND ARTERIAL SPIN-TAGGING (1999) (0)
ratsalveolar epithelial fluid clearance in adult Dexamethasone and thyroid hormone pretreatment (2015) (0)
Single inhaler triple therapy in patients with COPD: response rates in health-related quality of life in the IMPACT Trial (2018) (0)
EFFECT OF ONCE-DAILY SINGLE-INHALER FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL TRIPLE THERAPY ON EXACERBATIONS COMPARED WITH BUDESONIDE/FORMOTEROL DUAL THERAPY IN PATIENTS WITH COPD AND NO HISTORY OF EXACERBATIONS: A POST HOC ANALYSIS OF THE FULFIL STUDY (2021) (0)
Differential responses of native and exotic coastal sage scrub plant species to N additions and the soil microbial community (2013) (0)
EFFECT OF AGE ON EFFICACY AND SAFETY OF ONCE-DAILY SINGLE-INHALER TRIPLE THERAPY FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL IN PATIENTS WITH COPD: A POST-HOC ANALYSIS OF THE IMPACT TRIAL (2019) (0)
COMPARISON BETWEEN UMEC/VI AND FF/VI BASED ON BASELINE FEV1 REVERSIBILITY: SUB-ANALYSIS FROM THE IMPACT TRIAL (2019) (0)
The Influence of Altered Rainfall Regimes on Early Season N Partitioning Among Early Phenology Annual Plants, a Late Phenology Shrub, and Microbes in a Semi-arid Ecosystem (2014) (0)
GENETIC VARIANTS DO NOT PREDICT ACUTE COPD EXACERBATIONS OR TREATMENT RESPONSE TO FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) AND ITS COMPONENTS (2020) (0)
P247 Umeclidinium/vilanterol (UMEC/VI) versus mono-bronchodilator therapy in steroid-free GOLD B patients with chronic obstructive pulmonary disease (COPD): the EMAX trial (2018) (0)
Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter] (2021) (0)
Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer? (2021) (0)
Top-down control of microbial activity and biomass in an Arctic soil ecosystememi (2010) (0)
PIN21 EMPIRIC ANTIBIOTIC PRRESCRIBING IN SUBJECTS WITH INFLUENZA IN A UNITED STATES COMMERCIALLY INSURED POPULATION (2010) (0)
COPD_A_331636 3105..3118 (2021) (0)
CORRELATION OF THE MULTIPLE INERT GAS ELIMINATION TECHNIQUE WITH VENTILATION/PERFUSION SCANNING USING NON-RADIOACTIVE HYPERPOLARIZED 3HE AND ARTERIAL SPIN TAGGING MRI (1999) (0)
Integrating Soil Microbiology into Ecosystem Science (2019) (0)
Improvements in lung function with umeclidinium/vilanterol analysed by reversibility at screening: a post hoc analysis of the EMAX trial (2021) (0)
Chest Radiography, Fluoroscopy, Angiography and Pulmonary Function Testing (2005) (0)
Upscaling Methane Flux From Plot Level to Eddy Covariance Tower Domains in Five Alaskan Tundra Ecosystems (2022) (0)
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS EXPERIENCING ON-TREATMENT EXACERBATIONS, ON-TREATMENT DEATH, OR PREMATURE STUDY TREATMENT WITHDRAWAL: THE IMPACT TRIAL (2020) (0)
Reply to: Triple Therapy Trials for COPD: Methodological Considerations in the Mortality Effect. (2021) (0)
Blood eosinophils and treatment response with triple and dual combination therapy in COPD: analysis of the IMPACT trial (2019) (0)
SINGLE-INHALER TRIPLE THERAPY FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL COMPARED WITH TIOTROPIUM MONOTHERAPY IN COPD: A POST HOC ANALYSIS BY AIRFLOW LIMITATION (2020) (0)
A Year in the Life: Annual Patterns of CO 2 and CH 4 from a Northern Finland Peatland, Including Anaerobic Methane Oxidation and Summer Ebullition Rates (2014) (0)
Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening (2018) (0)
Ecosystem and Community Responses to Rainfall Manipulations in Shrublands Depends on Dominant Vegetation Cover (2014) (0)
Autotrophic and Heterotrophic Controls over Winter Soil Carbon Cycling in a Subalpine Forest Ecosystem (2005) (0)
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial (2022) (0)
Improved Understanding of Methane Dynamics in Alaskan Tundra Ecosystems and a Temperate Peatland Ecosystem by Integrating Observational Data with the CLM-Microbe Model (2016) (0)
Non-native annuals in a semi-arid shrubland increase soil respiration rates and alter sensitivity to moisture and temperature (2012) (0)
A microbial biogeochemistry network for soil carbon and nitrogen cycling and methane flux: model structure and application to Asia (2017) (0)
POLES APART: ANAEROBIC DEHALORESPIRATION IN ARCTIC PEATS OF THE NORTH SLOPE (2018) (0)
Chemical and Physical Controls, and Microbial Implications, on Methane Fluxes During an Unusually Warm Spring Thaw in Barrow, Alaska (2015) (0)
Single inhaler triple therapy in patients with COPD: patient-reported dyspnoea and health status from the IMPACT Trial (2018) (0)
Corrigendum to “Imaging physiological parameters with hyperpolarized gas MRI” Progress in NMR Spectrosc. 47 (2005) 187 (2006) (0)
Molecular Mirror Technology Facilitates High-Throughput, Accurate SARS-CoV-2 Testing (2021) (0)
Critical Care/Respiratory Care Gastrointestinal Complications of Acute Respiratory Failure (2003) (0)
Direct Imaging Of Delayed And Collateral Ventilation In COPD Using Hyperpolarised Gas MRI (2012) (0)
Characterising patients with COPD by baseline short-acting β2-agonist (SABA) use: a post hoc analysis of the EMAX trial (2020) (0)
All-Cause Mortality by Subgroup in Patients with Chronic Obstructive Pulmonary Disease: Post Hoc Analysis of the IMPACT Trial (2021) (0)
COPD_A_215011 809..819 (2020) (0)
Comparative Efficacy of Umeclidinium/Vilanterol, Umeclidinium and Salmeterol in Symptomatic Patients with Chronic Obstructive Pulmonary Disease Free of Inhaled Corticosteroids: The EMAX Trial (2019) (0)
Rescue Medication Use as an Indicator of Symptom Burden in Patients with COPD: A Post Hoc Analysis of the EMAX Trial (2020) (0)
The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: A Pre-Specified Analysis of Safety According to Age (2019) (0)
Improvements in COPD Symptoms with Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial (2020) (0)
Mortality Risk and Serious Cardiopulmonary Events in Moderate-to-Severe COPD: Post Hoc Analysis of the IMPACT Trial. (2022) (0)
The IMPACT Trail: Single Inhaler Triple Therapy vs. dual therapies: Consistent benefit across multiple exacerbation endpoints (2019) (0)
InforMing the PAthway of COPD Treatment (The IMPACT Study): Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: An Analysis Based on Baseline COPD Medication Use (2019) (0)
COPD_A_291967 499..517 (2021) (0)
Preventing Clinically Important Deterioration with Umeclidinium/Vilanterol Versus Bronchodilator Monotherapy in Patients with Chronic Obstructive Pulmonary Disease Free of Inhaled Corticosteroids: A Prospective Analysis of the EMAX Trial (2019) (0)
COPD Assessment Test (CAT) Score Is Associated with Risk of Future Exacerbation: An Analysis from the IMPACT Trial (2019) (0)
InforMing the PAthway of COPD Treatment (IMPACT Study)-Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results Based on an Analysis of the North American Region (2019) (0)
The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Cardiovascular Safety (2019) (0)
Preventing Clinically Important Deterioration (CID) of COPD with Single-inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol: A Prospective Analysis of the IMPACT Trial (2019) (0)
COPD_A_295835 1215..1226 (2021) (0)
Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed to Treat Analysis of the EMAX Trial (2020) (0)
Comparative Efficacy of Once-Daily Umeclidinium and Twice-Daily Salmeterol in Symptomatic Patients with Chronic Obstructive Pulmonary Disease Free of Inhaled Corticosteroids: Results from the EMAX Trial (2019) (0)
S101 The impact of smoking on improving COPD outcomes with umeclidinium/vilanterol: a pre-specified analysis of the EMAX trial (2019) (0)
P244 Defining the minimum clinically important difference (MCID) for the evaluating respiratory symptoms in COPD daily diary using global anchors: data from the FULFIL study (2018) (0)
The IMPACT Trial: Single Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients with COPD: Results on Rescue Use and Night-Time Awakenings (2019) (0)
Reply to Wang and Lai: The Role of Eosinophils during the Withdrawal of Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David A. Lipson?

David A. Lipson is affiliated with the following schools:

San Diego State University
Stanford University
University of Colorado
University of Pennsylvania